ESMO 2022 | Elucidating HRRm status in patients with mCRPC in the PROpel trial

Andrew Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, discusses findings from the Phase III PROpel trial (NCT03732820) which assessed tumor tissue and circulating tumor DNA (ctDNA) in patients with metastatic castrate-resistant prostate cancer (mCRPC) for mutations in homologous recombination repair (HRR) genes. Tissue tumor and blood samples were collected with liquid biopsies conducted and both types of samples were found to concordantly elucidate the HRR mutation status of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.